Latest multiple sclerosis Stories

EAST HANOVER, N.J., May 8, 2012 /PRNewswire/ -- Phil Keoghan, host of "The Amazing Race," and the women cyclists of the professional "NOW and Novartis for MS" team are joining with Novartis Pharmaceuticals Corporation for a second year in a row to raise awareness of MS. The campaign, "Together in MS," will support the MS community and show that MS does not have to define the more than 400,000 people in the U.S. living with the disease. To view the multimedia assets associated...

Researchers studying multiple sclerosis (MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves. Nearly a decade ago, a group at Mayo Clinic found a new enzyme, called Kallikrein 6, that is present in abundance in MS lesions and blood samples and is associated with inflammation and demyelination in other neurodegenerative diseases. In a study published this month in Brain Pathology, the same group...

NEW BRAUNFELS, Texas, April 27, 2012 /PRNewswire/ -- One hundred and eighty miles -- Houston to Austin, Texas -- that's the challenge bike riders in the BP MS 150 overcame on April 21 and 22 in a fund-raising event for Multiple Sclerosis. Team Freedom, a corporate team sponsored by The SCOOTER Store, the nation's leading provider of power mobility solutions and services, completed the two-day ride and raised over $12,000 for the cause. (Logo:...

ARMONK, N.Y., April 26, 2012 /PRNewswire/ -- IBM (NYSE: IBM) today announced that researchers from The State University of New York (SUNY) at Buffalo are using IBM analytics technology to study more than 2,000 genetic and environmental factors that may contribute to multiple sclerosis (MS) symptoms. (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO) As part of the initiative, Researchers will tap into IBM's analytics technology to develop algorithms for big data...

HOUSTON, April 24, 2012 /PRNewswire/ -- This past weekend on April 21-22, 2012, 34 partners, associates, staff, family and friends of Susman Godfrey L.L.P. rode 170 miles from Houston to Austin as part of the BP MS150. As part of that ride, the team's members have raised almost $180,000 to support research to find a cure and treatment for multiple sclerosis. For the first year, this makes Susman Godfrey the event's largest law firm team fundraiser. More important, Team Susman...

(Ivanhoe Newswire) – According to a recent study, people who received injections of the multiple sclerosis (MS) drug interferon beta-1a directly after noticing signs of possible MS were less likely to progress into definite MS compared to those who switched to interferon beta-1a from placebo. Although it is not currently available in the United States, the trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is available in all European Union...

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New...

NEW ORLEANS, April 19, 2012 /PRNewswire-USNewswire/ -- People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at...

(Ivanhoe Newswire) -- An oral drug called ONO-4641 is under investigation because it can reduce the number of lesions in people with multiple sclerosis (MS). The study involved 407 people between the ages of 18 and 55 who had relapsing-remitting MS.  They were given placebo randomly of .05mg, .10mg, or .15 mg of ONO-4641 once per day for 26 weeks.  Patients who had two or more relapses in the two years prior to the study, were included, along with those who had one or more relapses...

ALISO VIEJO, Calif., April 17, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 64th Annual Meeting of the American Academy of Neurology (AAN), taking place in New Orleans, LA, at the Ernest N. Morial Convention Center from April 21 through 28, 2012. Following are details about the data presentation: Title: Burden of Pseudobulbar Affect Among Patients With Multiple...